

Ref no: 024220519
From: Public
Date: 22/05/19
Subject: Treatments in the Trust

REQUEST

Within your health trust how many patients are, within the past 6 months that you have data available, being treated with the following treatments? This is regardless for the disease being treated.

Disodium pamidronate (Aredia)
Ibandronic acid or ibandronate (Bondronat)
Sodium clodronate (Bonefos, Clasteon, Loron)
Zoledronic acid or zoledronate (Zometa)

Denosumab (Xgeva)
Omalizumab [Xolair]
Mepolizumab [Nucala]
Reslizumab [Cinqaero]
Benralizumab [Fasenra]

How many paediatric patients have been treated in the last 6 months with Xolair/omalizumab?

RESPONSE

Data JAC Pharmacy Drug Issues 20th December 2018 to 20th May 2019
Count of patients Issued by selected drug.
(A Paediatric issue is determined if the date of birth is greater than 1st January 2001)

	Adult	Paed
DENOSUMAB 60 mg/1ml Pre-filled syringe	6	0
IBANDRONIC ACID 150 mg Tablets	5	0
IBANDRONIC ACID 3 mg/3mL Pre-filled syringe	5 or less	0
IBANDRONIC ACID 50 mg Tablets	5 or less	0
OMALIZUMAB 'XOLAIR' 150 mg/1ml Pre-filled syringe	50	6
SODIUM CLODRONATE 800 mg Tablets	6	0
ZOLEDRONIC ACID 4 mg Injection	15	0
ZOLEDRONIC ACID 5 mg/100ml Injection	5 or less	0

Please note: We are unable to provide precise figures when these are five or less due to the risk that individuals will be identified, as we are required to protect their identity under the

Data Protection Act. In such circumstances sections 40(2) and (3) of the Freedom of Information Act apply. In this case, our view is that disclosure would breach the first data protection principle. This states that personal data should be processed fairly and lawfully. It is the fairness aspect of this principle which, in our view, would be breached by disclosure. In such circumstances section 40 confers an absolute exemption on disclosure. There is, therefore, no public interest test to apply.